Bexarotene and Malignant neoplasm progression - a phase IV clinical study of FDA data

Summary:

Malignant neoplasm progression is reported as a side effect among people who take Bexarotene (bexarotene), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Vitamin B12, and have Hepatitis b.

The phase IV clinical study analyzes which people have Malignant neoplasm progression when taking Bexarotene. It is created by eHealthMe based on reports of 614 people who have side effects when taking Bexarotene from the FDA, and is updated regularly.

What is Bexarotene?

Bexarotene has active ingredients of bexarotene. eHealthMe is studying from 616 Bexarotene users. Check the latest studies of Bexarotene.

What is Malignant neoplasm progression?

Malignant neoplasm progression (cancer tumour came back) is found to be associated with 1,510 drugs and 1,635 conditions by eHealthMe. Check the latest studies of Malignant neoplasm progression.

On Jul, 30, 2026

614 people reported to have side effects when taking Bexarotene.
Among them, 24 people (3.91%) have Malignant neoplasm progression.

Could Bexarotene cause Malignant neoplasm progression?

Among these 24 people:

How long have people been on Bexarotene when they have Malignant neoplasm progression? *

What is the gender of people who have Malignant neoplasm progression when taking Bexarotene? *

female: 43.48 %
male: 56.52 %

What is the age of people who have Malignant neoplasm progression when taking Bexarotene? *

What are other drugs people take besides Bexarotene? *

What are other side effects people have besides Malignant neoplasm progression? *

Drug Ineffective: 4 people, 16.67%
Nausea (feeling of having an urge to vomit): 4 people, 16.67%
Neuropathy Peripheral (surface nerve damage): 3 people, 12.50%
Malaise (a feeling of general discomfort or uneasiness): 3 people, 12.50%
Hypertriglyceridaemia (excess of triglycerides in the blood): 2 people, 8.33%
T-Cell Lymphoma (a blood cell cancer): 2 people, 8.33%
Drowsiness: 1 person, 4.17%
Dizziness: 1 person, 4.17%
Taste - Impaired: 1 person, 4.17%
Electrocardiogram Qt Prolonged: 1 person, 4.17%

What are the existing conditions these people have? *

Hepatitis B: 5 people, 20.83%
Mycosis Fungoides (lymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin): 4 people, 16.67%
T-Cell Lymphoma (a blood cell cancer): 2 people, 8.33%
Mycosis Fungoides Stage Ii (any amount of the skin surface is covered with patches and/or plaques. lymph nodes are enlarged but cancer has not spread to them): 2 people, 8.33%
Squamous Cell Carcinoma (a cancer of a kind of epithelial cell): 1 person, 4.17%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 4.17%
Pain: 1 person, 4.17%
Neoplasm Malignant (cancer tumour): 1 person, 4.17%
Lymphoma (cancer that begins in immune system cells): 1 person, 4.17%
Kidney Transplant Rejection: 1 person, 4.17%

* Approximation only. Some reports may have incomplete information.

Do you take Bexarotene and have Malignant neoplasm progression?

- Check whether Malignant neoplasm progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Bexarotene:

Bexarotene (616 reports)

Browse all side effects of Bexarotene:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Malignant neoplasm progression:

Malignant neoplasm progression (1,510 drugs)

Browse all the conditions that are associated with Malignant neoplasm progression:

Malignant neoplasm progression (1,635 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on bexarotene (the active ingredients of Bexarotene) and Bexarotene (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.